Dynamic Technology Lab Private Ltd Makes New $326,000 Investment in Vera Therapeutics, Inc. $VERA

Key Points

• Dynamic Technology Lab Private Ltd has made a new investment in Vera Therapeutics, purchasing 13,570 shares valued at approximately $326,000.
• Institutional investors currently own about 99.21% of Vera Therapeutics, with several hedge funds recently increasing their stakes in the company.
• Vera Therapeutics reported a quarterly earnings per share (EPS) of ($1.20), missing expectations, and equity analysts predict the company will post -$2.89 EPS for the current fiscal year.

Dynamic Technology Lab Private Ltd bought a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 13,570 shares of the company's stock, valued at approximately $326,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Price T Rowe Associates Inc. MD grew its stake in shares of Vera Therapeutics by 8.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,754,832 shares of the company's stock valued at $114,212,000 after purchasing an additional 377,783 shares during the last quarter. Vestal Point Capital LP grew its stake in shares of Vera Therapeutics by 132.6% in the 1st quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company's stock valued at $60,050,000 after purchasing an additional 1,425,000 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of Vera Therapeutics by 18.4% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,675,367 shares of the company's stock valued at $40,243,000 after purchasing an additional 260,188 shares during the last quarter. Woodline Partners LP grew its stake in shares of Vera Therapeutics by 20.1% in the 4th quarter. Woodline Partners LP now owns 1,202,466 shares of the company's stock valued at $50,852,000 after purchasing an additional 201,573 shares during the last quarter. Finally, Deutsche Bank AG lifted its holdings in shares of Vera Therapeutics by 10.2% in the 1st quarter. Deutsche Bank AG now owns 892,859 shares of the company's stock valued at $21,446,000 after buying an additional 82,483 shares during the period. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Vera Therapeutics Price Performance

VERA stock traded up $1.80 during midday trading on Thursday, hitting $26.34. 1,747,208 shares of the stock were exchanged, compared to its average volume of 1,755,185. The stock's 50-day moving average price is $22.39 and its 200-day moving average price is $23.15. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of -7.36 and a beta of 1.17. Vera Therapeutics, Inc. has a fifty-two week low of $18.53 and a fifty-two week high of $51.61. The company has a debt-to-equity ratio of 0.16, a quick ratio of 17.03 and a current ratio of 17.03.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.38). During the same period in the previous year, the business earned ($0.62) earnings per share. Research analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on VERA shares. HC Wainwright reissued a "buy" rating and issued a $85.00 price target (up from $75.00) on shares of Vera Therapeutics in a report on Monday, June 2nd. JPMorgan Chase & Co. reduced their price target on Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Guggenheim reissued a "buy" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Scotiabank reissued an "outperform" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Vera Therapeutics in a report on Thursday. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $63.00.

Insider Transactions at Vera Therapeutics

In other news, Director Patrick G. Enright acquired 209,393 shares of Vera Therapeutics stock in a transaction that occurred on Monday, June 23rd. The stock was purchased at an average cost of $20.87 per share, with a total value of $4,370,031.91. Following the completion of the acquisition, the director owned 3,569,522 shares in the company, valued at $74,495,924.14. This trade represents a 6.23% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 16.30% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.